2m 2m 2m 2m 2m 2m 2m
ARTIVA BIOTHRP (ARTV)
NASDAQ
$6.89+$0.02 (+0.28%)
Price as of Jun 03, 2026 6:59 PM EDT- $385.3MMarket Cap
- 252.31%1-Year Change
- BiotechnologyIndustry
ARTIVA BIOTHRP (ARTV)
$6.89+$0.02 (+0.28%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 0 -100.00% | 251,000 N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 0 -100.00% | 251,000 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | |
Research and Development Expense | -76,000 -97.60% | -3.2M N/A | |
Depreciation and Amortization Expense | 2.6M +6.83% | 2.4M N/A | |
Total Operating Expenses | 89.8M +32.99% | 67.5M N/A | |
Operating Profit | -89.8M +33.48% | -67.3M N/A | |
Interest Income | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 5.9M +211.42% | 1.9M N/A | |
Income before Taxes | -89.8M +37.38% | -65.4M N/A | |
Income Taxes | 0 N/A | 0 N/A | |
Extraordinary Items | 0 N/A | 0 N/A | |
Net Income | -83.9M +28.29% | -65.4M N/A | |
Net Income from Continuing Operations Applicable to Common | -83.9M +28.29% | -65.4M N/A | |
Basic EPS and Net Income | -3.43 -40.96% | -5.81 N/A | |
Diluted EPS and Net Income | -3.43 -40.96% | -5.81 N/A | |
Basic Weighted Average Shares | 24.4M +117.11% | 11.3M N/A | |
Diluted Weighted Average Shares | 24.4M +117.11% | 11.3M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 26.7M -33.64% | 40.2M N/A | |
Short-Term Investments | 81.3M -44.00% | 145.2M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 108.0M -41.75% | 185.4M N/A | |
Total Current Assets | 112.7M -40.27% | 188.6M N/A | |
Accumulated Depreciation | 8.5M +42.78% | 5.9M N/A | |
Property and Plant and Equipment and Net | 6.6M +3.89% | 6.4M N/A | |
Total Long-Term Assets | 458,000 +71.54% | 267,000 N/A | |
Total Assets | 130.9M -37.52% | 209.6M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | |
Total Current Liabilities | 13.1M +6.81% | 12.3M N/A | |
Total Long-Term Debt | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 73,000 0.00% | 73,000 N/A | |
Total Liabilities | 21.0M -8.59% | 22.9M N/A | |
Retained Earnings | -330.5M +34.00% | -246.7M N/A | |
Total Stockholders Equity | 110.0M -41.08% | 186.6M N/A | |
Total Shares Outstanding | 24.3M 0.00% | 24.3M N/A | |
Cash Flow | |||
Cash from Operating Activities | -76.8M +39.47% | -55.0M N/A | |
Capital Expenditures | 2.6M +302.96% | 642,000 N/A | |
Cash from Investing Activities | 63.4M +152.64% | -120.5M N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 9,000 -99.99% | 162.2M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | |
Return on Assets | -49.26% N/A | N/A N/A | |
Return on Equity | -56.55% N/A | N/A N/A | |
Revenue Growth | -100.00% N/A | N/A N/A | |
Current Ratio | 8.61 N/A | N/A N/A | |
Cash Ratio | 2.04 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow